Suzhou, July 28, 2021 — Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of subjects in its phase I clinical trial of GT20029 in China.

The phase I trial is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of GT20029 (gel/tincture) following topical single and multiple ascending dose administration in healthy subjects.

GT20029 is the first topical Proteolysis Targeting Chimera (PROTAC) compound globally to enter the clinical stage. The China Center for Drug Evaluation (CDE) and the U.S. Food and Drug Administration (FDA) cleared GT20029's phase I clinical trial for treating androgenetic alopecia (AGA) and acne in April 2021 and July 2021 separately.

Dr. Youzhi Tong, Founder, Chairman and Chief Executive Officer of Kintor Pharmaceutical, commented, “The initiation of this study represents a significant milestone for Kintor, as it is the first topical PROTAC compound to enter the clinical stage in the world and demonstrates our progress in developing innovative therapeutics for unmet medical needs. In preclinical studies, topical GT20029 has been shown to avoid systemic exposure and many of the side effects of oral drugs for AGA and acne. This phase I trial will enable us evaluate the safety, recommended dosage and dosing frequency of GT20029 to benefit those who suffer from AGA and acne.”